


HLS Therapeutics®

Gilbert Godin | CEO
Tim Hendrickson | CFO

Q1 2021 Results Conference Call
May 6, 2021

Forward-looking statements

Certain statements in this presentation are “forward-looking statements”. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, assumptions or future events or performance (often, but not always using words or phrases such as “project”, “forecast”, “target”, “expect”, “seek”, “endeavour”, “anticipate”, “plan”, “estimate”, “believe”, “intend”, or stating that certain actions, events or results may, could, should, would, might or will occur or be taken, or achieved) are not statements of historical fact and may be “forward-looking statements”. Forward-looking statements are based on expectations, estimates and projections at the time the statements are made that involve a number of known and unknown risks and uncertainties which would cause actual results or events to differ materially from those presently anticipated. A number of factors could cause actual results, performance or achievements to be materially different from any future results, performance or achievements that may be expressed or implied by such forward-looking statements. Should one or more of these risks or uncertainties materialize, or should assumptions underlying the forward-looking statements prove incorrect, actual results, performance or achievements could vary materially from those expressed or implied by the forward-looking statements contained in this presentation. These factors should be considered carefully and prospective investors should not place undue reliance on these forward-looking statements. Although the forward-looking statements contained in this presentation are based upon what HLS currently believes to be reasonable assumptions, HLS cannot assure prospective investors that actual results, performance or achievements will be consistent with these forward-looking statements. Except as required by law, HLS does not have any obligation to advise any person if it becomes aware of any inaccuracy in or omission from any forward-looking statement, nor does it intend, or assume any obligation, to update or revise these forward-looking statements to reflect new events or circumstances.

*** All figures in USD unless otherwise noted.**

Canadian Cardiovascular Society adds **Vascepa** to its Lipid Management Guidelines

2021 Canadian Cardiovascular Society Guidelines for the Management of Dyslipidemia for the Prevention of Cardiovascular Disease in the Adult

Glen J. Pearson PharmD , George Thanassoulis MD ,
Todd J. Anderson MD , Arden R. Barry PharmD ,
Patrick Couture MD, PhD , Natalie Dayan MD ,
Gordon A. Francis MD , Jacques Genest MD , Jean Grégoire MD ,
Steven A. Grover MD , Milan Gupta MD , Robert A. Hegele MD ,
David Lau MD, PhD , Lawrence A. Leiter MD ,
Alexander A. Leung MD , Eva Lonn MD , G. B. John Mancini MD ,
Priya Manjoo MD , Ruth McPherson MD, PhD , Daniel Ngui MD ,
Marie-Eve Piché MD, PhD , Paul Poirier MD, PhD ,
John Sievenpiper MD, PhD , James Stone MD, PhD ,
Rick Ward MD , Wendy Wray RN, MScN

PII: S0828-282X(21)00165-3
DOI: https://doi.org/10.1016/j.cjca.2021.03.016
Reference: CJCA 4009

To appear in: *Canadian Journal of Cardiology*




"We recommend the use of icosapent ethyl to lower the risk of CV events in patients with ASCVD, or with diabetes and ≥1 CVD risk factors, who have an elevated fasting triglyceride level of 1.5-5.6 mmol/L despite treatment with maximally tolerated statin therapy."
(Strong Recommendation; High-Quality Evidence)

"We do not recommend the use of over-the-counter omega-3 polyunsaturated fatty acids supplements (marketed as natural health products in Canada) to reduce CVD risk."
(Strong Recommendation; High-Quality Evidence)

Provided May 6, 2021, as part of an oral presentation and is qualified by such, contains forward-looking statements, actual results may vary materially; HLS disclaims any duty to update.


Vascepa: prescription momentum growing…

Weekly script data since launch



Source: Weekly Rx, 2020 - 2021, IQVIA


…despite a constrained environment



Source: IQVIA

Provided May 6, 2021, as part of an oral presentation and is qualified by such, contains forward-looking statements, actual results may vary materially; HLS disclaims any duty to update.


Vascepa Recent Analogues: two-year comparison



	Launch	Daily Cost	Q1	Q2	Q3	Q4	Q5	Q6	Q7	Q8
Vascepa	**Feb 2020**	**$9.80**	417	1,454	2,639	4,050	5,525	8-14K	14-32K	36-65K
Eliquis	**Dec 2012**	**$3.20**	23	110	192	672	5,438	12,008	23,692	57,184
Pradaxa	**Nov 2010**	**$3.20**	164	388	559	431	770	1,733	2,345	3,402

Provided May 6, 2021, as part of an oral presentation and is qualified by such, contains forward-looking statements, actual results may vary materially; HLS disclaims any duty to update.


**Source: IQVIA Analogue Planner, Q2 2020*



HLS Therapeutics®

Gilbert Godin | CEO
Tim Hendrickson | CFO

Q1 2021 Results Conference Call
May 6, 2021


HLS Therapeutics®
Q&A